Akebia Therapeutics Inc
NASDAQ:AKBA
Akebia Therapeutics Inc
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 426 full-time employees. The company went IPO on 2014-03-20. The firm is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of altitude on oxygen availability. In addition, it has a commercial product, Auryxia (ferric citrate), which is marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with dialysis-dependent (DD)-CKD or the hyperphosphatemia indication, and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis dependent (NDD)-CKD or the IDA indication. Its ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with CKD.
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 426 full-time employees. The company went IPO on 2014-03-20. The firm is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of altitude on oxygen availability. In addition, it has a commercial product, Auryxia (ferric citrate), which is marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with dialysis-dependent (DD)-CKD or the hyperphosphatemia indication, and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis dependent (NDD)-CKD or the IDA indication. Its ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with CKD.
Revenue Growth: Akebia reported Q3 2025 total revenue of $58.8 million, up from $37.4 million in the same period last year, driven by both Vafseo and Auryxia sales.
Vafseo Launch: Vafseo generated $14.3 million in revenue this quarter, with more prescriptions in its first 41 weeks than any recent dialysis launch, although overall Q3 demand was flat versus Q2.
Patient Access Expansion: Prescribing access for Vafseo expanded from 40,000 patients at the start of the year to nearly 70,000 by the end of Q3 and over 260,000 currently, with DaVita rolling out access to its 200,000 patients.
Operational Challenges: Adherence and protocol issues, especially with initial refills and titration, continued to impact new patient starts and inventory, but efforts are underway to improve education and processes.
Positive Clinical Data: Recent post-hoc analyses from the INNOVATE trial showed Vafseo patients had a lower risk of death or hospitalization compared to controls, generating enthusiasm among prescribers.
Auryxia Sales: Auryxia sales remained strong at $42.5 million, with no new generic competitors entering the market yet, though future sales are uncertain.
